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Abstract
BACKGROUND
Untreated neonatal cholestasis can progress to liver cirrhosis and end stage liver
disease in infancy due to prolonged hepatocyte and biliary tree injury and may
require liver transplantation. Therefore, non-invasive evaluation of hepatic
fibrosis is important in infants with cholestasis.
AIM
To investigate the usefulness of periportal thickening (PT) measured on liver
magnetic resonance imaging (MRI) for the assessment of hepatic fibrosis in
infants with cholestasis including biliary atresia (BA).
METHODS
This retrospective study included infants less than 6 mo who underwent liver
MRI and biopsy for the evaluation of infantile cholestasis. PT and spleen size
were measured on MRI. Serologic assessment was based on aspartate
transaminase to platelet ratio index (APRI). The grade of histopathologic fibrosis
was assessed by the METAVIR grading system. Correlation and diagnostic
performance of PT, normalized spleen size ratio (SR, using the upper normal size
limit), and APRI for diagnosing hepatic fibrosis were obtained by receiver-
operating characteristic (ROC) curve analysis.
RESULTS
A total of 155 patients were included, 110 of which were diagnosed with BA.
Mean age at the time of MRI was 57.6 ± 34.4 d. There were positive correlations
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between fibrosis grade and PT and SR, even after adjusting age (all, P < 0.001).
For the diagnosis of significant fibrosis (METAVIR grade F2-F4), the area under
the ROC curve was 0.899 (95%CI: 0.840–0.941) for PT (cutoff, 4.2 mm), which was
higher than 0.741 (95%CI: 0.664–0.808) for SR and 0.712 (95%CI: 0.634–0.782) for
APRI (both, P < 0.001). For the diagnosis of cirrhosis (F4), the area under the ROC
curve was the highest with SR as 0.790 (95%CI: 0.718–0.852).
CONCLUSION
Liver MRI findings of PT and SR are useful to assess clinically significant hepatic
fibrosis (F2 and higher) in infants with cholestasis including BA.
Key words: Infants; Cholestasis; Biliary atresia; Liver; Fibrosis; Magnetic resonance
imaging
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: Non-invasive evaluation of hepatic fibrosis is important in infants with
cholestasis including biliary atresia. Periportal thickening (PT) and normalized spleen
size ratio (SR) measured on liver magnetic resonance imaging (MRI) showed positive
correlations with hepatic fibrosis grade, even after adjusting age. For the diagnosis of
significant fibrosis (F2-F4), PT using the cutoff of 4.2 mm showed higher diagnostic
performance than SR or aspartate transaminase to platelet ratio index. For the diagnosis
of cirrhosis (F4), SR was the best. Therefore, liver MRI findings of PT and SR can be
useful to assess clinically significant hepatic fibrosis (F2 and higher) in infants with
cholestasis.
Citation: Lee MH, Shin HJ, Yoon H, Han SJ, Koh H, Lee MJ. Periportal thickening on
magnetic resonance imaging for hepatic fibrosis in infantile cholestasis. World J




Neonatal cholestasis, an intrahepatic or extrahepatic disorder, is defined as persistent
conjugated  hyperbilirubinemia  more  than  2  wk  and  may  be  caused  by  various
diseases[1]. Untreated neonatal cholestasis can progress to liver cirrhosis or end stage
liver disease in infants due to prolonged hepatocyte and biliary tree injury and may
require liver transplantation. Ultimately, the degree of hepatic fibrosis in infantile
cholestasis is a major determinant of the patient's outcome[2]. For biliary atresia (BA), a
previous study reported that severe hepatic fibrosis at the time of Kasai operation,
irrespective of age, carried a poor outcome and the degree of hepatic fibrosis, as well
as the time of operation, is an important factor for survival after Kasai operation[3,4].
Therefore,  knowing the degree of  hepatic  fibrosis  before  the  operation can help
predict the treatment methods and outcomes of patients and prepare for subsequent
liver transplants.
Hepatic fibrosis in neonates and infants can be measured by serology, ultrasound
elastography, and liver biopsy[5]. Ultrasound elastography is non-invasive, but has the
disadvantage that the accuracy of the test may be impaired if the practitioner lacks
experience or if ascites exists in the perihepatic space. Liver biopsy is necessary for
confirmation of  biliary  disease  including BA as  an  accurate  diagnostic  tool  and
assessment of hepatic fibrosis, but it is an invasive method and has the disadvantage
that it cannot be repeatedly performed due to complications of the test itself[6,7].
Magnetic resonance imaging (MRI) has been reported to be useful for differential
diagnosis of cholestatic jaundice in infants with high resolution and quantitative
evaluation[8]. Several previous studies investigating diagnosis of BA by MRI evaluated
visibility of the extrahepatic bile duct on MR cholangiopancreatography (MRCP)[9-11],
but it has been reported that the accuracy of BA diagnosis was improved when the
triangular cord thickness or periportal thickening (PT), which is usually measured on
ultrasonography, was applied to MRI[12].  We thought if  these MRI findings were
associated  with  hepatic  fibrosis,  degree  of  hepatic  fibrosis  could  be  predicted
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noninvasively and reproducibly by making less susceptible to practitioner’s skill than
ultrasonography. However, there was no previous study showing that MRI findings
including PT reflect the degree of hepatic fibrosis in patients with infantile cholestasis.
Therefore,  we investigated whether  the PT and spleen size  measured on MRI is
associated with pathologically assessed hepatic fibrosis in patients with infantile
cholestasis.
MATERIALS AND METHODS
This retrospective study was approved by our Institutional Review Board, with a
waiver  for  informed  consent  for  reviewing  medical  records  and  images  of  the
patients.  However, written informed consent for sedation and MRI was received
before each examination as routine clinical practice.
Patients and basic characteristics
We included all consecutive patients between July 2009 and October 2017 who (1)
underwent  both  liver  MRI  and  liver  biopsy  to  evaluate  the  cause  of  infantile
cholestasis which was defined as prolonged hyperbilirubinemia longer than 2 wk; (2)
were younger than 6 mo at the time of MRI as identified by chart review; and (3) had
an interval between liver MRI and liver biopsy within 1 mo. We do liver MRI and
liver biopsy in infants with persistent jaundice after conservative treatment. We also
do liver biopsy during BA and choledochal cyst operation in neonates and infants as a
routine protocol. Patient’s sex and age at the time of MRI, laboratory results at the
time of MRI and etiology of cholestasis confirmed by pathology and/or operative
cholangiography (BA vs non-BA) were evaluated through medical chart review.
MRI acquisition and interpretation
All MR images were obtained using a 1.5-T unit (Intera Achieva; Philips Healthcare)
with  a  cardiac  coil  and  patients  were  sedated  by  general  anesthesia  under  the
supervision  of  anesthesiologists.  MR  sequences  used  at  our  hospital  included
respiratory gated T2-weighted fast spine echo (FSE) axial, T1-weighted spin echo
axial, T2-weighted single shot FSE sagittal, and respiratory gated FSE 3 dimensional
MRCP coronal  images.  Repetition time/echo time was  2000/100 ms for  FSE T2,
600/11 for T1, 700/80 for single shot FSE T2, and 1500/650 for MRCP. Matrix was 256
× 256. Section thickness was 2 mm with 1 mm gap for MRCP and 3 mm without gap
for the others. Field of view was 18-24 cm. The total scan time for our protocol was
approximately 15 -20 min for most of the cases.
Two radiologists (with 15 and 4 years of clinical experience in pediatric radiology,
respectively) who were unaware of the final diagnosis analyzed the MR images in
consensus  on  the  picture  archiving  and  communication  system  (Centricity;  GE
Healthcare).  The PT measured on MRI was defined as  the maximal  thickness  of
periportal signal change on MRI which was measured (1) either along the right main
or left main portal vein; and (2) on either side of the portal vein where its thickness
was  the  greatest.  The  maximum  thickness  of  the  periportal  signal  change  was
separately  measured on  T1-weighted  axial,  T2-weighted  axial  and T2-weighted
sagittal  images,  and then  the  largest  value  among the  three  measurements  was
selected (Figure 1)[12]. The size of the spleen was defined as the maximum length of
spleen either measured on T2-weighted axial or sagittal images, and the larger value
was used for analysis. Then we analyzed the normalized spleen size ratio (SR)[13] by
calculating the maximum spleen length divided by the upper normal limit of size
according to the patient’s age and sex[14].
Liver biopsy and histologic grade
Basically, ultrasonography-guided liver biopsy was performed using an 18-gauge
core biopsy needle (TSK Stericut Standard type with Co-axial; TSK) with a free-hand
technique under sedation supervised by anesthesiologists in patient with infantile
cholestasis. However, if BA or choledochal cyst was strongly suspected, liver biopsy
was performed during operation.
All  specimens were evaluated for histopathologic diagnosis of cholestasis and
grading  hepatic  fibrosis  by  hepatobiliary  pathologists.  The  fibrosis  grades  of
pathologic specimens of all cases were evaluated by METAVIR fibrosis grade, ranging
from grade F0 to F4 (F0,  no fibrosis;  F1,  portal  fibrosis  without septa;  F2,  portal
fibrosis with few septa;  F3,  numerous septa without cirrhosis;  and F4,  cirrhosis).
Clinically significant fibrosis was defined as grade F2 to F4 and advanced fibrosis was
defined as grade F3 to F4[15,16].
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Figure 1
Figure 1  Example of measuring of periportal thickening on magnetic resonance imaging. Pancreaticobiliary
magnetic resonance imaging of a 3-mo-old girl diagnosed as biliary atresia. A: On T1-weighted axial image, the
maximal thickness of periportal signal change was measured on right main portal vein where its greatest thickness
was 5.5 mm; B: On T2-weighted sagittal image, the maximal thickness of periportal signal change was 6.1 mm.
Therefore, the larger of the two, which was measured on T2-weighted sagittal image, was defined as periportal
thickening of this patient.
Serologic evaluation
Laboratory results included aspartate aminotransferase (AST), alanine transaminase
and platelet count. We calculated the AST-to-platelet ratio index (APRI), known as a
noninvasive fibrosis score by serology, which is calculated as [(AST/upper limit of
normal AST) × 100]/platelet count (109/L).
Statistical analysis
Statistical  analyses  were  performed  using  SPSS  version  23  (IBM  Corp.).  The
independent two-sample t  test for continuous variables and χ2  test for categorical
variables were used. Analysis of variance was used for the comparison of parameters
with different hepatic fibrosis grades. Correlation between laboratory or imaging
parameters and hepatic fibrosis grades was analyzed using Kendall’s tau correlation
coefficient. The diagnostic performances of parameters for clinically significant or
advanced fibrosis and cirrhosis were evaluated by a receiver operating characteristic
(ROC)  curve  analysis.  The  optimal  cut-off  values  from  the  ROC  curves  were
determined  by  the  Youden  index.  The  area  under  the  ROC curve  (AUC)  of  the




During  the  study  period,  155  patients  with  infantile  cholestasis  were  included.
Baseline characteristics of our study are summarized in Table 1. The mean age at the
time of  MRI  was  57.6  ±  34.4  d  and 94  patients  (60.6%)  were  female.  Among the
patients, 110 infants (71%) were diagnosed with BA and the remaining 45 (29%) were
diagnosed  with  diseases  other  than  BA  by  pathologic  confirmation.  The  final
diagnoses of the non-BA patients were choledochal cyst (n = 29), hepatitis (n = 8),
paucity of intrahepatic bile ducts (n = 3), and other metabolic diseases (n = 5).
The mean age at the time of MRI was not different between the BA and non-BA
groups (P = 0.303). The PT and SR were significantly higher in the BA group than in
the non-BA group (P < 0.001), but ARPI was not different (Table 1). The number of
patients with clinically significant fibrosis (F2–F4) was 113 (72.9%), with 105 from the
BA  group  and  8  from  the  non-BA  group.  There  were  47  patients  (30.3%)  with
advanced fibrosis (F3–F4), with 46 from the BA group and 1 from the non-BA group.
The distribution of each hepatic fibrosis grade is detailed in Table 1. There were 9 BA
and 1 non-BA patients with liver cirrhosis (F4).
Comparison and correlation between parameters and hepatic fibrosis grades
Table 2 summarizes the results of parameters in each fibrosis grading group. Age,
APRI,  PT,  and  SR  were  different  in  the  fibrosis  group  comparison.  Correlation
analysis also demonstrated positive correlation between these parameters and fibrosis
grades  (all,  P  <  0.001).  However,  after  adjusting  age,  partial  correlation  results
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Table 1  Clinical summary of the patients with infantile cholestasis
Overall (n = 155) BA (n = 110) Non-BA (n = 45) P value
Demographics
Age (d) 57.6 ± 34.4 59.7 ± 30.3 52.4 ± 42.8 0.303
Gender (M:F) 61:94 41:69 20:25 0.470
Laboratory results
APRI 1.32 ± 1.61 1.47 ± 1.66 0.95 ± 1.42 0.069
Imaging findings
PT (mm) 4.9 ± 1.8 5.7 ± 1.4 2.9 ± 0.9 < 0.001
SR 1.02 ± 0.20 1.07 ± 0.19 0.91 ± 0.17 < 0.001
METAVIR grades (Patients’ number)
F0/F1/F2/F3/F4 32/10/66/37/10 1/4/59/37/9 31/6/7/0/1 < 0.001
P values from independent t-test except for gender and fibrosis grades from χ2 test. BA: Biliary atresia; APRI:
Aspartate transaminase to platelet ratio index; SR: Normalized spleen size ratio; PT: Periportal thickening.
demonstrated that only PT (τ = 0.518, P < 0.001) and SR (τ = 0.340, P < 0.001) showed
positive correlations with the hepatic fibrosis grades. Representative images of each
hepatic fibrosis grade are shown in Figure 2.
Assessment of diagnostic performance of parameters for clinically significant or
advanced fibrosis and cirrhosis
The diagnostic performances in diagnosing clinically significant fibrosis (F0–F1 vs
F2–F4),  advanced fibrosis  (F0–F2  vs  F3–F4),  and cirrhosis  (F0-F3  vs  F4)  for  each
parameter are shown in Table 3. The AUCs of PT were 0.899 (95%CI: 0.840–0.941)
using a cutoff value of 4.2 mm for clinically significant fibrosis and 0.734 (95%CI:
0.657–0.801) with a cutoff of 5.3 mm for advanced fibrosis (P < 0.001). The AUCs of SR
and APRI were 0.741 with a cutoff value of 0.85 and 0.712 with a cutoff of 0.44 for the
diagnosis of clinically significant fibrosis,  respectively.  For diagnosing advanced
fibrosis, the AUC of SR was 0.742 with a cutoff value of 1.1 and that of APRI was 0.724
with a cutoff value of 0.78. For diagnosing cirrhosis, the AUC was the highest with SR
as 0.790 (95%CI: 0.718-0.852) with a cutoff value of 1.04. However, the AUC of PT was
not significant (P = 0.058).
Comparison of diagnostic performance of parameters for clinically significant or
advanced fibrosis and cirrhosis
For diagnosing clinically significant fibrosis, there was a significant difference in the
AUC between PT and SR (difference between area, 0.158; P < 0.001) and PT and APRI
(difference between area, 0.186; P < 0.001), but no significant difference between SR
and APRI (difference between area, 0.029; P  = 0.613). The AUC of PT (0.899) was
significantly higher than those of SR (0.741) and APRI (0.712) (Figure 3A).
In contrast, there were no significant differences in the AUCs between PT, SR and
APRI for diagnosing advanced fibrosis. The differences between areas were 0.008 (P =
0.873) between PT and SR, 0.009 (P = 0.859) between PT and APRI, and 0.018 (P =
0.724) between SR and APRI (Figure 3B).
In cirrhosis, the AUC with SR was higher than that with PT (difference between
area, 0.135; P = 0.041), but not that with APRI (difference between area, 0.075; P =
0.427).  There  was  no  significant  difference  in  the  AUCs  between  PT  and  APRI
(difference of 0.060, P = 0.626) (Figure 3C).
DISCUSSION
Serologic  marker  of  APRI  and  splenomegaly  are  well  known  markers  for  the
evaluation  of  hepatic  fibrosis  in  adults,  but  there  is  limited  study  about  these
parameters in infants. Moreover, this is the first study suggested the usefulness of PT
for investigating hepatic fibrosis in infants with cholestasis. We demonstrated that PT
measured on MRI showed positive correlation with pathologically assessed hepatic
fibrosis grades and had good performance to diagnose both clinically significant
fibrosis and advanced fibrosis with cutoff values of 4.2 mm and 5.3 mm, respectively.
In addition, hepatic fibrosis was also significantly correlated with SR and APRI, but
the diagnostic performance of PT measured on MRI for clinically significant hepatic
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Table 2  Comparison and correlation analyses for fibrosis grading
Age (d) APRI PT (mm) SR
Hepatic fibrosis group comparison
F0 (n = 32) 40.8 ± 34.8 1.12 ± 1.63 3.1 ± 1.1 0.89 ± 0.15
F1 (n = 10) 60.6 ± 44.0 0.46 ± 0.38 3.3 ± 1.3 0.94 ± 0.20
F2 (n = 66) 52.3 ± 31.0 1.14 ± 1.23 5.2 ± 1.4 1.01 ± 0.17
F3 (n = 37) 71.9 ± 28.6 2.00 ± 2.27 5.9 ± 1.6 1.12 ± 0.20
F4 (n = 10) 89.7 ± 26.6 1.52 ± 0.55 5.7 ± 1.6 1.21 ± 0.17
P value < 0.001 0.026 < 0.001 < 0.001
Correlation analysis
Overall correlation
τ 0.313 0.326 0.448 0.361
P value < 0.001 < 0.001 < 0.001 < 0.001
Partial correlation with adjusting age
τ 0.071 0.518 0.340
P value 0.405 < 0.001 < 0.001
P values from analysis of variance for group comparisons and Kendall’s tau for correlation analyses. APRI:
Aspartate transaminase to platelet ratio index; PT: Periportal thickening, SR: Normalized spleen size ratio.
fibrosis was superior to that of SR and APRI. Moreover, after adjusting age, only PT
and SR showed positive correlations with the hepatic fibrosis grades. Therefore, our
study shows that MRI findings of PT and SR are useful in predicting the degree of
hepatic fibrosis in infants with cholestasis who cannot easily undergo liver biopsy.
To determine grade of hepatic fibrosis in patients with neonatal cholestasis, liver
biopsy is the gold standard. However, it is invasive and can result in severe, life-
threatening complications in infants and neonates[17-19]. Moreover, this procedure is
associated with significant sampling error[20].  Therefore, several methods for non-
invasive assessment of hepatic fibrosis in infants and neonates have been proposed.
APRI by laboratory test could be a reliable method to assess advanced fibrosis (F3–F4)
and liver cirrhosis (F4) at the time of Kasai operation and postoperative follow-up
care[21]. APRI has shown significant correlation with hepatic fibrosis grade in children
with chronic liver disease[5]. These studies are consistent with our study, in which
APRI of our patients showed significant correlation with hepatic fibrosis grade and
good performance to diagnose clinically significant fibrosis and advanced fibrosis.
However, APRI was not correlated with hepatic fibrosis grades after adjusting age.
Another tool is transient elastography, which could suggest optimal time of Kasai
operation in patients with BA[22]. There have been several reports on the utility of this
technique to evaluate hepatic fibrosis and cirrhosis in patients with BA[23-25]. However,
there are limitations in the aforementioned studies in that they could not evaluate the
diagnostic  performance  of  clinically  significant  fibrosis  (F2–F4)  and  operator
dependency of this method[7,23,25,26].
Triangular cord sign or PT was a concept originally designed for ultrasound, which
is represented by triangular cone-shaped fibrous tissue in the bifurcation of the portal
vein at the porta hepatis. However, due to operator dependence on ultrasound, the
concept of PT measured on MRI has been proposed and defined as a thickening of
periportal  signal  change  on  T1  or  T2-weighted  images[27,28].  A  recent  study  also
proposed that an MRI-based decision tree for diagnosis of BA using PT on MRI with a
cutoff value of 5.1 mm showed high sensitivity (97.3%) and specificity (94.8%)[12]. PT
measured on ultrasonography was associated with hepatic fibrosis in BA, but there
was no significant association between PT and hepatic fibrosis grade[23]. And there
was a few previous study on whether PT measured on MRI is associated with hepatic
fibrosis  in  patients  with neonatal  cholestasis  with relatively small  population[28].
Because this  was a retrospective study and there were limited data about PT on
ultrasonography in non-biliary atresia patients, we could not evaluate the diagnostic
performance of PT on ultrasonography compared with that on MRI. However, as
ultrasonography is a more available and easily accessible technique, further study is
needed for this topic.
Degree of hepatic fibrosis at time of Kasai operation is known to be one of the
prognostic  factors  after  Kasai  operation in  patients  with  BA[3,29].  Many previous
studies have focused on age at time of surgery, but a few studies have suggested that
severe fibrosis  at  the time of  Kasai  operation,  irrespective of  age,  carries  a  poor
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Figure 2
Figure 2  Representative images of periportal thickening for each hepatic fibrosis grade. The maximal thickness (double arrow in each figure) of periportal
signal intensity change was measured. A: 2.7 mm on axial T2-weighted image in a 7-d-old girl with non-biliary atresia (non-biliary atresia, choledochal cyst) and
hepatic fibrosis grade 1 (F1); B: 4.2 mm on T2-weighted axial image in a 2-mo-old girl with BA and F2; C: 5.5 mm on T1-weighted axial image in a 3-mo-old girl with
biliary atresia and F3; D: 5.4 mm on T2-weighted axial image in a 2-mo-old girl with non-biliary atresia (metabolic disease) and F4.
outcome[3,30].  Severe  fibrosis  was  associated with  unsuccessful  outcome of  Kasai
operation without biliary drainage and all  patients with cirrhosis  had no biliary
drainage after  Kasai  operation in a previous study[4].  Therefore,  in patients with
advanced  fibrosis  and  liver  cirrhosis  at  the  time  of  diagnosis,  early  liver
transplantation may improve prognosis over Kasai portoenterostomy[23,31].  A few
retrospective studies  suggested that  anti-inflammatory and immunomodulatory
drugs such as steroids might alter progression of hepatic fibrosis and improve biliary
drainage and survival rate of native liver of patients[32].  Considering that hepatic
fibrosis progresses even after surgery, degree of hepatic fibrosis both before and after
surgery could be associated with postoperative complications and prognosis in BA. A
prospective study is needed on whether the imaging findings of PT are also relevant
to the patient's prognosis.
There  were  several  limitations  in  this  study.  First,  this  study  was  performed
retrospectively, so inherent possibility of bias exists. Second, reproducibility of PT
measurements could be problematic, even though we used consensus reading. Third,
we could not evaluate the pathologic finding of PT. The meaning of PT as a direct or
indirect finding of hepatic or periportal fibrosis should be evaluated. Finally, the
number of patients with F1 and F4 was relatively small, leading to unreliable data
from these groups.
In conclusion, liver MRI findings of PT and SR can be useful to assess hepatic
fibrosis in infants with cholestasis including BA. The finding of PT with a cutoff value
of 4.2 mm has better diagnostic performance to predict clinically significant fibrosis
than either SR or APRI. And SR had the highest diagnostic performance value for
differentiating cirrhosis. The degree of hepatic fibrosis is an important prognostic
factor after Kasai operation in patients with BA. Therefore, PT and SR measured on
MRI may help predict  prognosis  of  BA and suggest  more effective non-invasive
treatment options.
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Table 3  Diagnostic performance of the parameters
Variable Cutoff value Sensitivity (%) Specificity (%) AUC 95%CI P value
Clinically significant fibrosis (F2-F4)
APRI 0.44 84.1 59.5 0.712 0.634-0.782 0.001
PT 4.2 mm 81.4 85.7 0.899 0.840-0.941 < 0.001
SR 0.85 85.0 54.8 0.741 0.664-0.808 < 0.001
Advanced fibrosis (F3-F4)
APRI 0.78 78.7 63.0 0.724 0.647-0.793 < 0.001
PT 5.3 mm 66.0 71.3 0.734 0.657-0.801 < 0.001
SR 1.1 61.7 78.7 0.742 0.666-0.809 < 0.001
Cirrhosis (F4)
APRI 1.24 90.0 70.3 0.715 0.637-0.785 0.002
PT 5.3 mm 70.0 62.1 0.656 0.675-0.730 0.058
SR 1.04 90.0 61.4 0.790 0.718-0.852 < 0.001
AUC: Area under the curve; APRI: Aspartate transaminase to platelet ratio index; PT: Periportal thickening; SR: Normalized spleen size ratio.
Figure 3
Figure 3  Comparisons of receiver operating characteristic curves. The comparisons of area under the curve (AUC) for diagnosing A: Clinically significant fibrosis
(F2-F4); B: Advance fibrosis (F3-F4); C: Cirrhosis (F4) with periportal thickening (PT, green line), normalized spleen size ratio (SR, orange line), and aspartate
aminotransferase to platelet ratio index (APRI, blue line). The AUC of PT for diagnosing clinically significant fibrosis was higher than that of SR or APRI. However, the
AUCs were not different for differentiating advanced fibrosis. For diagnosing cirrhosis, SR had higher AUC value than PT. APRI: Aspartate aminotransferase to
platelet ratio index; SR: Normalized spleen size ratio; PT: Periportal thickening.
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Untreated neonatal cholestasis can progress to liver cirrhosis or end stage liver disease in infants
due to prolonged hepatocyte and biliary tree injury and may require liver transplantation.
Therefore, non-invasive evaluation of hepatic fibrosis is important in infants with cholestasis
including biliary atresia.
Research motivation
Some serologic tests and splenomegaly are known markers for the evaluation of hepatic fibrosis
in adults, but there is limited study about these parameters in infants. Periportal thickening (PT)
was only considered as the finding of biliary atresia and has not been evaluated for assessing
hepatic fibrosis in infants with cholestasis.
Research objectives
We investigated whether the PT and spleen size measured on magnetic resonance imaging (MRI)
is associated with pathologically assessed hepatic fibrosis in patients with infantile cholestasis
including biliary atresia.
Research methods
This retrospective study included infants less than 6 mo with liver MRI and biopsy for the
evaluation of infantile cholestasis.  Not only PT and spleen size measured on MRI, but also
serologic assessment of aspartate transaminase to platelet ratio index (APRI) were evaluated and
compared with histopathologic METAVIR grading of hepatic fibrosis. We calculated normalized
spleen size ratio (SR) using the upper normal size limit.
Research results
A total of 155 patients were evaluated including 110 with biliary atresia. Mean age at the time of
MRI was 57.6 ± 34.4 d. There were positive correlations between fibrosis grade and PT and SR,
even after adjusting age. The finding of PT with a cutoff value of 4.2 mm has better diagnostic
performance to predict clinically significant fibrosis than either SR or APRI. And SR had the
highest diagnostic performance value for differentiating cirrhosis.
Research conclusions
Liver MRI findings of PT and SR are useful to assess clinically significant hepatic fibrosis (F2 and
higher) in infants with cholestasis including biliary atresia.
Research perspectives
The degree of hepatic fibrosis is an important prognostic factor after Kasai operation in patients
with biliary atresia. Therefore, PT and SR measured on MRI may help predict prognosis of
biliary atresia and suggest more effective non-invasive treatment options.
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